疾病相关脑激活预测类风湿关节炎对TNF抑制的临床应答(PreCePra):一项随机、多中心、双盲、安慰剂对照的3期研究
在德国、葡萄牙和塞尔维亚6个风湿病中心开展的3期随机双盲安慰剂对照试验中,139例活动性类风湿关节炎患者按基线功能MRI疼痛激活体积分层后2:1随机分配至赛妥珠单抗聚乙二醇化组或安慰剂组。第12周低疾病活动度达标率在高体积赛妥珠单抗组为57%、低体积赛妥珠单抗组为44%、安慰剂组为26%,高体积组与安慰剂组差异有统计学意义(p=0.0017),与低体积组差异无统计学意义(p=0.063)。
要点
- 高疾病相关fMRI中枢疼痛激活可能预测类风湿关节炎患者对TNF抑制剂的临床应答。
- 第12周低疾病活动度达标率:高体积赛妥珠单抗组57%、低体积赛妥珠单抗组44%、安慰剂组26%。
- 高体积赛妥珠单抗组与安慰剂组差异有统计学意义(p=0.0017),与低体积组差异无统计学意义(p=0.063)。
核心结论
- 高疾病相关fMRI中枢疼痛激活可能预测类风湿关节炎患者对TNF抑制剂治疗的临床应答。
研究设计与样本
- 3期、多中心、双盲、安慰剂对照、平行组随机试验,在德国、葡萄牙和塞尔维亚6个风湿病中心开展。
- 139例活动性类风湿关节炎患者(年龄≥18岁,至少使用一种传统合成改善病情抗风湿药后仍活动)按基线fMRI高体积或低体积分层,以2:1随机分配至赛妥珠单抗聚乙二醇化组或安慰剂组。
- 赛妥珠单抗聚乙二醇化给药方案为第0、2、4周皮下注射400 mg,之后每2周200 mg,最长24周。
- 主要结局为第12周达到低疾病活动度(28关节疾病活动度评分≤3.2)的患者比例,在意向治疗人群中分析。
- 研究于2013年9月3日至2020年1月10日筛查148例患者,随机分配139例(女性99例[71%],男性40例[29%])。
主要发现
- 高体积赛妥珠单抗组49例、低体积赛妥珠单抗组43例、安慰剂组47例。
- 第12周低疾病活动度达标率:高体积赛妥珠单抗组28例(57%)、低体积赛妥珠单抗组19例(44%)、安慰剂组12例(26%)。
- 高体积赛妥珠单抗组与安慰剂组差异有统计学意义(p=0.0017),与低体积赛妥珠单抗组差异无统计学意义(p=0.063)。
- 治疗相关不良事件共25例:赛妥珠单抗聚乙二醇化组22例,安慰剂组3例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis is an inflammatory disease frequently treated with TNF inhibitors. Little is known about predictors of response to TNF inhibitors. Because clinical response in rheumatoid arthritis is measured by composite scores containing subjective patient-orientated domains (eg, pain and global disease perception), we hypothesised that patients with high disease representation in the CNS might respond better to TNF inhibitors than patients with less CNS disease representation. METHODS: We did a phase 3, multicentre, double-blind, placebo-controlled, parallel-group randomised trial in patients with active rheumatoid arthritis at six rheumatology centres across Germany, Portugal, and Serbia. All patients had a functional MRI (fMRI) brain scan at baseline to measure CNS pain activation. Patients (aged ≥18 years) with active rheumatoid arthritis who have active disease despite the use of at least one conventional synthetic disease-modifying antirheumatic drug were stratified according to fMRI (high volume or low volume) and were randomly assigned 2:1 using a randomisation list generated by a study statistician to treatment with the TNF inhibitor certolizumab pegol (400 mg subcutaneously on weeks 0, 2, and 4, and 200 mg once every 2 weeks for maximum 24 weeks) or placebo. Patients and clinicians were masked to allocation. The primary outcome was the proportion of patients reaching low disease activity (Disease Activity Score in 28 joints ≤3·2) at week 12, analysed in the intention-to-treat population. There was no lived experience involvement in study design. The study was registered with EudraCT (2013-000337-13) and ClinicalTrials.gov (NCT01864265). FINDINGS: Between Sept 3, 2013, and Jan 10, 2020, 148 patients with rheumatoid arthritis were screened and 139 (99 [71%] women and 40 [29%] men) were randomly assigned to the high-volume certolizumab pegol group (n=49), the low-volume certolizumab pegol group (n=43), or the placebo group (n=47). Low disease activity was reached by 28 (57%) in the high-volume certolizumab pegol group, 19 (44%) in the low-volume certolizumab pegol group, and 12 (26%) in the placebo group at week 12. Response in the high-volume certolizumab pegol group was significantly different (p=0·0017) to the placebo group, but not the low-volume certolizumab pegol group (p=0·063). There were 25 treatment-related adverse events: 22 in the certolizumab pegol groups and three in the placebo group. INTERPRETATION: High disease-associated fMRI CNS pain activation might predict clinical response of patients with rheumatoid arthritis to TNF inhibitor treatment. FUNDING: UCB Biopharma.
引用
- Hess A, Tascilar K, Schenker HM, et al. Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study. Lancet Rheumatol. 2025. PMID: 40570879. doi:10.1016/S2665-9913(25)00032-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。